NEOK001: A New Bispecific Antibody–Drug Conjugate for Advanced Prostate Cancer

A promising new experimental drug called NEOK001 (also known as ABL206) is emerging as a potential therapy for advanced cancers that express two specific proteins on their surface: B7‑H3 and ROR1. Among these cancers, prostate cancer is one of the tumor types where early data already show signs of activity, making NEOK001 a candidate of interest for patients with aggressive or treatment‑resistant disease.

The compound is scheduled to enter clinical trials in early 2026, initially as a Phase 1 study in solid tumors.

NEOK001 is a bispecific antibody–drug conjugate (ADC). This means it is a targeted antibody that simultaneously binds two different antigens, in this case, B7‑H3 and ROR1, and is linked to a powerful chemotherapy drug called exatecan, a topoisomerase I inhibitor.

The idea behind this bispecific design is to improve tumor selectivity and efficacy. By requiring binding to both B7‑H3 and ROR1, NEOK001 aims to concentrate its cytotoxic payload mainly on cancer cells that co‑express these two proteins, while sparing normal tissues that may express only one of them.

B7‑H3 (CD276) is a tumor‑associated immune regulator that is overexpressed in many advanced prostate cancers, including castration‑resistant prostate cancer (CRPC) and neuroendocrine variants. High B7‑H3 levels are associated with worse prognosis, more aggressive disease, and resistance to standard therapies.

ROR1 is an embryonic protein that is normally turned off in adult tissues but is re‑expressed in several cancers, including prostate cancer. In prostate tumors, ROR1 overexpression is linked to more aggressive biology, including features of cancer stem cells, epithelial–mesenchymal transition (EMT), and chemoresistance.

Because both proteins are present on at least a subset of prostate cancers but are more restricted in normal tissues, they represent attractive targets for precision ADC therapy.

In laboratory and animal studies, NEOK001 has demonstrated several key features:

Enhanced cytotoxicity: In cell‑based assays, NEOK001 is more potent than monospecific ADCs targeting either B7‑H3 or ROR1 alone.
Strong antitumor activity in xenograft models: In patient‑derived xenograft (PDX) models, NEOK001 produced tumor growth inhibition in 81% of 37 PDX models, and tumor regression in 54%, across multiple cancer types.

Activity in prostate cancer models: Among the prostate PDX models tested, 2 out of 5 showed meaningful responses, indicating that at least some prostate tumors are sensitive to this dual targeting strategy. \

These results suggest that NEOK001 can effectively kill tumor cells that co‑express B7‑H3 and ROR1, while leveraging their combined expression pattern to limit off‑target toxicity. Safety profile on animal models was good, with mild to moderate reversible side effects.

Patients with advanced prostate cancer whose tumors express both B7‑H3 and ROR1 may become eligible once trial sites begin enrolling specific tumor types and biomarker‑selected cohorts.

Source.